• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名因皮质类固醇诱导免疫抑制的患者出现皮肤利什曼病的不寻常临床表现。

Unusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid-induced immunosuppression.

作者信息

Mahdavi Maryam, Aryan Reihaneh, Nahidi Yalda, Teimoorian Mehrdad, Mashayekhi Vahid

机构信息

Cutaneous Leishmaniasis Research Center Mashhad University of Medical Sciences Mashhad Iran.

Golestan University of Medical Sciences Gorgan Iran.

出版信息

Clin Case Rep. 2020 Nov 24;9(1):133-136. doi: 10.1002/ccr3.3482. eCollection 2021 Jan.

DOI:10.1002/ccr3.3482
PMID:33489148
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7813036/
Abstract

Clinicians should always consider rare, atypical, and opportunistic infections in patients undergoing long-term systemic corticosteroid therapy. Diagnosis needs further evaluations and special consideration.

摘要

临床医生在长期接受全身皮质类固醇治疗的患者中应始终考虑罕见、非典型和机会性感染。诊断需要进一步评估和特殊考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/7813036/e1fdb2380775/CCR3-9-133-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/7813036/252ebeaa68ce/CCR3-9-133-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/7813036/fef83b98cb18/CCR3-9-133-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/7813036/e1fdb2380775/CCR3-9-133-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/7813036/252ebeaa68ce/CCR3-9-133-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/7813036/fef83b98cb18/CCR3-9-133-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/7813036/e1fdb2380775/CCR3-9-133-g003.jpg

相似文献

1
Unusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid-induced immunosuppression.一名因皮质类固醇诱导免疫抑制的患者出现皮肤利什曼病的不寻常临床表现。
Clin Case Rep. 2020 Nov 24;9(1):133-136. doi: 10.1002/ccr3.3482. eCollection 2021 Jan.
2
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS.一名艾滋病患者在内脏疾病后发生播散性皮肤利什曼病。
J Am Acad Dermatol. 2004 Mar;50(3):461-5. doi: 10.1016/j.jaad.2003.10.005.
3
Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids - first report.系统性糖皮质激素治疗后2年皮肤利什曼病复发——首例报告
Int J Dermatol. 2007 Jun;46(6):628-30. doi: 10.1111/j.1365-4632.2006.03096.x.
4
PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.合并感染HIV的利什曼病患者的皮肤利什曼病后皮肤黏膜病变及其他皮肤病变：与免疫反应相关的临床表现综述
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3258. doi: 10.1371/journal.pntd.0003258. eCollection 2014.
5
Atypical presentations of cutaneous leishmaniasis: A systematic review.皮肤利什曼病的非典型表现：一项系统综述。
Acta Trop. 2017 Aug;172:240-254. doi: 10.1016/j.actatropica.2017.05.022. Epub 2017 May 17.
6
Atypical Mycobacterial Infection Arising Amid Corticosteroid Therapy for Livedoid Vasculopathy.在治疗类脂质渐进性坏死性血管病的皮质类固醇治疗期间出现的非典型分枝杆菌感染。
Case Rep Dermatol Med. 2019 Oct 7;2019:1840280. doi: 10.1155/2019/1840280. eCollection 2019.
7
Cutaneous alternariosis: role of corticosteroid-induced cutaneous fragility.皮肤链格孢菌病：皮质类固醇诱导的皮肤脆性的作用
Dermatology. 1996;193(4):342-4. doi: 10.1159/000246287.
8
Disseminated cutaneous leishmaniasis in HIV positive patient--a case report.HIV阳性患者的播散性皮肤利什曼病——病例报告
Niger J Med. 2010 Jan-Mar;19(1):112-4. doi: 10.4314/njm.v19i1.52501.
9
Case Report: An Atypical Erysipeloid Presentation of Cutaneous Leishmaniasis from the Hilly Region of Nepal.病例报告：尼泊尔山区不典型类丹毒样皮肤利什曼病。
Am J Trop Med Hyg. 2021 May 10;105(1):134-137. doi: 10.4269/ajtmh.20-0595.
10
Leishmania infantum leishmaniasis in corticosteroid--treated patients.皮质类固醇治疗患者中的婴儿利什曼原虫病
BMC Infect Dis. 2006 Dec 18;6:177. doi: 10.1186/1471-2334-6-177.

本文引用的文献

1
Old world cutaneous leishmaniasis in Iran: clinical variants and treatments.伊朗的旧世界皮肤利什曼病：临床变种与治疗方法
J Dermatolog Treat. 2021 Nov;32(7):673-683. doi: 10.1080/09546634.2019.1704214. Epub 2020 Jan 8.
2
Case Report: Diffuse Cutaneous Leishmaniasis by in a Patient Undergoing Immunosuppressive Therapy: Risk Status in an Endemic Mediterranean Area.病例报告：免疫抑制治疗患者中 导致的弥漫性皮肤利什曼病：在地中海流行地区的风险状况。
Am J Trop Med Hyg. 2018 May;98(5):1313-1316. doi: 10.4269/ajtmh.17-0769. Epub 2018 Mar 22.
3
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
一名接受免疫抑制治疗的患者出现内脏和黏膜皮肤利什曼病复发。
BMC Infect Dis. 2017 Jul 7;17(1):478. doi: 10.1186/s12879-017-2571-x.
4
Infection Risk and Safety of Corticosteroid Use.使用皮质类固醇的感染风险与安全性
Rheum Dis Clin North Am. 2016 Feb;42(1):157-76, ix-x. doi: 10.1016/j.rdc.2015.08.004. Epub 2015 Oct 24.
5
Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature.抗肿瘤坏死因子诱发的内脏利什曼病和皮肤利什曼病：病例报告及文献综述
Dermatology. 2015;230(3):204-7. doi: 10.1159/000370238. Epub 2015 Jan 23.
6
Leishmaniasis.利什曼病。
J Infect. 2014 Nov;69 Suppl 1:S10-8. doi: 10.1016/j.jinf.2014.07.016. Epub 2014 Sep 17.
7
Leishmaniasis in immunosuppressed individuals.免疫抑制个体中的利什曼病。
Clin Microbiol Infect. 2014 Apr;20(4):286-99. doi: 10.1111/1469-0691.12556. Epub 2014 Feb 20.
8
Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review.器官移植受者中局限性皮肤利什曼病的传播：病例报告及文献综述
Int J Dermatol. 2013 Jan;52(1):59-62. doi: 10.1111/j.1365-4632.2012.05615.x.
9
Disseminated leishmaniasis caused by Leishmania tropica in HIV-positive patients in the Islamic Republic of Iran.伊朗伊斯兰共和国HIV阳性患者中由热带利什曼原虫引起的播散性利什曼病。
East Mediterr Health J. 2010 Mar;16(3):340-3.
10
The innate immune response against Leishmania parasites.针对利什曼原虫寄生虫的固有免疫反应。
Immunobiology. 2008;213(3-4):377-87. doi: 10.1016/j.imbio.2007.12.005. Epub 2008 Mar 4.